作者
Wael Alqarawi,Rafik Tadros,Jason D. Roberts,Christopher C. Cheung,Martin S. Green,Ian G. Burwash,Christian Steinberg,Jeff S. Healey,Habib Khan,Ciorsti McIntyre,Julia Cadrin-Touringy,Zachary Laksman,Christopher S. Simpson,Shubhayan Sanatani,Martin Gardner,Paul Angaran,Erkan İlhan,Mario Talajic,Laura Arbour,Richard Leather,Colette Seifer,Jacqueline Joza,Felicity Lee,Lawrence Lau,Girish M. Nair,George A. Wells,Andrew D. Krahn
摘要
There is growing evidence that mitral valve prolapse (MVP) is associated with otherwise unexplained cardiac arrest (UCA). However, reports are hindered by the absence of a systematic ascertainment of alternative diagnoses. This study reports the prevalence and characteristics of MVP in a large cohort of patients with UCA. Patients were enrolled following an UCA, defined as cardiac arrest with no coronary artery disease, preserved left ventricular ejection fraction, and no apparent explanation on electrocardiogram. A comprehensive evaluation was performed, and patients were diagnosed with idiopathic ventricular fibrillation (IVF) if no cause was found. Echocardiography reports were reviewed for MVP. Patients with MVP were divided into 2 groups: those with IVF (AMVP) and those with an alternative diagnosis (nonarrhythmic MVP). Patient characteristics were then compared. The long-term outcomes of AMVP were reported. Among 571 with an initially UCA, 34 patients had MVP (6%). The prevalence of definite MVP was significantly higher in patients with IVF than those with an alternative diagnosis (24 of 366 [6.6%] vs 5 of 205 [2.4%]; P = 0.03). Bileaflet prolapse was significantly associated with AMVP (18 of 23 [78%] vs 1 of 8 [12.5%]; P = 0.001; OR: 25.2). The proportion of patients with AMVP who received appropriate implantable cardioverter-defibrillator therapies over a median follow-up of 42 months was 21.1% (4 of 19). MVP is associated with otherwise UCA (IVF), with a prevalence of 6.6%. Bileaflet prolapse appears to be a feature of AMVP, although future studies need to ascertain its independent association. A significant proportion of patients with AMVP received appropriate implantable cardioverter-defibrillator therapies during follow-up.